CHCWM – Cancer & Hematology Centers of West Michigan

CP-MGC018-01 (MacroGenics)

A Phase I/II, First-in-Humans, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination with MGA012 (Anti-PD-1 Antibody) in Patients with Advanced Solid Tumors